Cancer treatment with a cell-based immunotherapy causes mild cognitive impairment, a Stanford Medicine team found. They also identified compounds that could treat it.
Category: neuroscience – Page 233
A Natural Molecule Shows Surprising Power Against Alzheimer’s
A hidden gut-brain protein may hold the key to stopping alcohol’s twin assault on the liver and the mind.
The Roots of Dementia Trace Back All The Way to Childhood, Experts Find
Dementia is often associated with older people, but it doesn’t just appear out of nowhere.
Platelet-inspired nanoparticles can boost brain-computer interface electrode performance
Scientists working to enhance brain-computer interface (BCI) technology—which allows people to control devices with their thoughts—have found they can improve the performance of electrodes implanted in the brain by targeted delivery of anti-inflammatory drugs.
V-STARS pioneers neuroscience at ESA’s Orbital Robotics Lab
As part of the ESA Academy Experiments Programme, Team V-STARS carried out the first experiment with human participants in the Orbital Robotics Lab, investigating how microgravity affects the perception of verticality.
The V-STARS team, a collaboration between Birkbeck, University of London, and the University of Kent (UK), was selected to join the ESA Academy Experiments Programme in February 2025. After obtaining ethical approval from the United Kingdom and authorisation from the ESA Medical Board, the team was permitted to carry out their experiment in the Orbital Robotics Lab (ORL), located at ESTEC, the ESA site in the Netherlands.
The campaign involved test subjects seated on the ORL’s floating platform, wearing VR headsets while performing gravity-related perceptual tasks. The project investigates the use of Vestibular Stochastic Resonance — a phenomenon in which controlled noise enhances the sensitivity of a sensory system — to improve perception and potentially accelerate adaptation to microgravity. Over two weeks, the team tested more than 20 participants and has now returned to their universities to analyse the results.
Glycemic status and macronutrient intake as predictors of sleep outcomes: an analysis of NHANES 2007–2020 data
BackgroundEmerging evidence suggests that glycemic status and dietary intake are associated with sleep duration and quality. ObjectiveTo examine associations…
Video NeuroImage: Stereotypic Motor Behaviors in a Patient With Pantothenate Kinase–Associated Neurodegeneration
A 24-year-old woman with pantothenate kinase–associated neurodegeneration (PKAN) presented with a 5-year history of psychiatric symptoms followed by prominent stereotypic motor behaviors, including repetitive touching of her mouth and leg, object manipulation, and tip-toe walking (Video 1). Examination revealed severe depression and anxiety, mild speech dysfluency, and the stereotypic movements. Previous symptomatic treatments provided limited benefit. Brain magnetic resonance imaging demonstrated the pathognomonic “eye-of-the-tiger” sign, indicative of iron deposition in the bilateral globus pallidus (Figure). Genetic testing identified compound heterozygous variants in the PANK2 gene: a known pathogenic variant (c.401AG) and a novel likely pathogenic variant (c.1465CG).
Simple Supplement Combo Calms Deadly Brain Cancer
A small human study shows resveratrol and copper reduced glioblastoma aggressiveness without side effects by targeting inflammatory DNA.
Early Dementia Symptoms Often Mistaken for Normal Ageing
Experts warn early dementia signs are often dismissed as ageing. Here are seven warning signs and why acting early matters.
A Review of the Clinical Progress of CT1812, a Novel Sigma-2 Receptor Antagonist for the Treatment of Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disease marked by the accumulation of toxic amyloid-beta (Aβ) oligomers. These oligomers are thought to cause synaptic dysfunction and contribute to neurodegeneration. CT1812 is a small-molecule sigma-2 receptor antagonist that is currently being investigated and tested as a potential disease-modifying treatment for AD. CT1812 acts by displacing Aβ oligomers into the cerebrospinal fluid and preventing their interaction with receptors on neurons. Preclinical studies and early clinical trials of CT1812 show promising results and provide evidence for its potential to slow AD progression. This review outlines the role of Aβ oligomers in AD, CT1812’s mechanism of action, and the effectiveness and limitations of CT1812 based on preclinical and clinical studies.